AccuGenomics

Executive Summary

AccuGenomics is a commercial-stage molecular diagnostics company that has developed SNAQ-SEQ, a novel quality control technology for next-generation sequencing (NGS). The company’s synthetic spike-in internal standards are added directly to patient samples to measure and correct both systematic and random errors in NGS assays, thereby eliminating false positives and false negatives. This capability is critical for applications requiring high accuracy, such as minimal residual disease (MRD) monitoring, liquid biopsy, and infectious disease detection. By enhancing the reliability of NGS results, AccuGenomics addresses a significant bottleneck in the clinical adoption of precision medicine. The company is based in Wilmington, North Carolina, and has been operating since 2015, focusing on partnerships with diagnostic laboratories and NGS platform providers. With the growing demand for accurate genomic testing, AccuGenomics’ solution is well-positioned to become a standard component in NGS workflows, potentially reducing error rates and improving patient outcomes.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major NGS platform provider70% success
• Q2 2026Clinical validation data publication for liquid biopsy80% success
• Q4 2026FDA clearance for MRD monitoring application60% success